Applications tied to the site
Partial coverage3 register records are within the point-match tolerance; a parcel boundary is needed to treat this as exact.
3 matchedSite planning risk brief
One-off house / within 5 km where a location match is available
Executive snapshot
11% of nearby decided applications were refused. The site check found 1,739 decisions within 5 km, 3 exact-site or onsite candidate records, and 134 structured appeals.
Evidence maturity
Each section reports its own coverage. “Not yet covered” means no conclusion is drawn while source datasets or policy extraction are still being loaded.
3 register records are within the point-match tolerance; a parcel boundary is needed to treat this as exact.
3 matchedCurrent indexed zoning and settlement layers are intersected with the selected site where coverage exists.
Current section-and-page citations have not yet been loaded for this authority.
Each layer reports its own coverage; missing coverage never appears as a clean result.
0 prompts are backed by extracted nearby decision evidence; all prompts remain checks, not predictions.
134 structured nearby appeal records.
134 matchedHistoric extracted references are not presented as current policy; verified citations are still being loaded.
Open preview
Open preview
Retention permission and permission for development that consists of the application seeking amendments to the permitted development (Louth County Council Reg. Ref 08/822 which has been extended in duration under Reg. Ref 18/187 and subsequent permission Reg. Ref. 18/817) and relate to the medium to large scale biopharmaceutical manufacturing facility, referred to as Site 2 in the planning permission. The over all GFA of the buildings on Site2 is proposed to increase by 513m2 from 54,232m2 to 54,745m2. Permission is sought to retain elements of the under construction development and permission to complete and reconfigure other elements as proposed in the application documents, as summarised below.... Permission- Revised entrance security gates, Corporate backlit signage to the northeast corner of Building DK2, Revised landscape proposals. Retention Permission 1. Revision to elevational treatments and building configuration. 2. Revisions to entrance details. 3. Addition of substation and switchroom in place of secondary security building and second substation. 4. Revision to parking, internal roads, yards and plant and services layouts. 5. Gas reducing station. 6. Additional cooling plant and associated stair core to building DK4. 7. Addition of electric vehicle charging points. The application relates to development which comprises, or is for the purposes of, an activity requiring an integrated pollution prevention and control licence and waste licence
The application seeks amendments to the permitted development (LCC Reg. Ref. 08/822), which has been extended in duration under Reg. Ref.18/187) and relate to the medium to large scale biopharmaceutical manufacturing facility, referred to as site 2 in the planning permission. The area of the overall site subject to amendments in this application is c.20.74 hectares. The overall GFA of builings on site 2 is proposed to reduce from 57,700m2 to 54,232m2. See Site Notice for Comprehensive Description of Amendments.
EXTENSION OF DURATION: Parent ref: 08/822 - Permission to develop an Advance Biopharmaceutical and Knowledge Industry Campus to include the construction of two advance manufacturing facilities to accommodate biopharmaeutical administration, research and support activities at the existing IDA site of 48.18ha area at Mullagharlin and Haynestown Townlands, Dundalk, Co. Louth. The biopharma manufacturing facilities with associated research and knowledge industry campus will consist of a medium to large scale biopharmaceutical manufacturing facility consisting of four storey development with plant room, approx 29,300sqm, a two storey development with plant room, part two storey warehouse, two 3storey untility buildings, two 4storey and 3storey offices, cafeteria all with a gross floor area of circa 57,700sqm. A small to medium scale biopharmaceutical manufacturing facility consisting of a primary manufacturing facility approx 13,000sqm, 2storey manufacturing facility with plant room, part 2storey warehouse, a single storey building, one 3storey office/ laboratory building, cafeteria all with a gross floor area of circa 23,350sqm. Both facilites shall include single storey pumphouses, utility yards and process water, waste water and miscellaneous bunded tanks, pipe bridges, miscellaneous items of external plant and equipment, 32m high discharge stacks and landscape features and associated car parking, internal roads, fencing, site lighting and utilities. The IDA advance facilities development proposals also include six 2storey office buildings with plant rooms, single storey security building, single storey 110kva sub-station with external transformers in compound area, 3 high tension electrical sub-stations, single storey water pumphouse, complete road network, car parking for circa 1,050cars, a series of internal vehicular and pedestrian entrances, site lighting, signage and flagpoles, extensive planted berm structures 5-12m high, decorative and surface water attenuation ponds, underground and overground services. A main estate entrance with signage and sculpture features, bus shelter/stops, site fencing and landscaping, cycle paths, footpaths, tree and shrub planting, external lighting and site furniture shall be constructed as part of site works. The facilities together with site infrastructure will be built in phases according to need during the 10year permission lifetime sought by this planning application
Permission for development of site at Mullagharlin/Haggardstown townlands, located on the IDA Ireland Dundalk Science and Technology Park. The overall site is accessed off the R215, the Southern Link Road and is generally south and east of Mullagharlin Road, north of the Marlbog Road and generally north and west of the Brookfield residential development. The proposed development consists of an integrated Pharmaceutical manufacturing facility located directly north of Wuxi Biopharmaceutical campus currently under construction. The proposed development comprises of the following: 1. A three storey Pharmaceutical manufacturing facility sized approximately 15,520 square metres and approximately 26 metres high and with roof mounted plant and equipment and stacks. 2. A four storey Administration and Laboratory building sized 8,789 square metres and approximately 22.5 metres high and with roof mounted plant and equipment and stacks. 3. A two storey modular support laboratory sized approximately 820 square metres and approximately 10.1 metres high and with roof mounted plant and equipment and stacks. 4. A single storey boiler unit area sized approximately 864 square metres and 9.6 metres high including two boiler stacks approximately 31 metres high. 5. 4 no. modular plant and equipment storage units sized approximately 35 square metres and 3 metres high per unit. 6. A single storey drum store sized approximately 75 square metres and 6 metres high. 7. A single storey waste store sized approximately 75 square metres and 6 metres high. 8. Site works including car park for 278 cars, docking areas, yard areas housing external plant, tanks and equipment, a large landscaped berm to the north and west of the facility, a surface water attenuation pond, roads and underground services, external lighting, security fencing, fire water tanks and modular housing for pumps, 2 no. vehicular entrances off the previously permitted internal road access currently under construction, bicycle shelters and facilities for E-car charging and disabled parking as well as all associated site works and landscaping. This application consists of development for an activity for which a licence under Part IV of the Environmental Protection Agency Act 1992, is required. An EIAR and Natura Impact Statement accompany this application.
Permission for revision and reconfiguration to the existing Planning Permission (Reg. Ref. No. 19/861) necessitated by a strategic, phased approach to construction of the permitted development envelope. The proposed development comprises: (1) A three storey biopharmaceutical manufacturing facility (sized approximately 10,275 square metres) with four storey administration and laboratory building (sized approximately 5,754 squre metres) all approximately 25 metres high and with roof mounted plant and equipment and stacks. (2) A single storey canteen with pedestrian link sized approximately 600 square metres and approximately 6.0 metres high. (3) Modifications will include revised and reconfigured internal layouts and elevations necessitated by the proposed strategic phased approach. (4) Relocation of 4 no. modular plant and equipment storage units sized approximately 45 square metres and 5 metres high per unit. (5) Relocation of 1 no. single storey drum store sized approximately 50 square metres and 6 metres high. (6) Relocation of 1 no. single storey waste store sized approximately 40 square metres and 5 metres high. (7) A new single storey electrical/transformer room approximately 100 square metres and 5 metres high. (8) A relocated single storey water pump house 140 square metres 6metres high with sprinkler tank 8 metres diameter 14 metres high and city water tank 10 metres diameter 15 metres high. (9) Siteworks including car park for 204 cars, docking areas, yard areas housing external plant, tanks and equipment, a large landscaped berm to the north and west of the facility, a surface water attenuation pond, roads and underground services, external lighting, security fencing, 2 no. vehicular entrances off the previously permitted internal road access currently under construction, bicycle shelters and facilities for E-car charging and disabled parking as well as all associated site works and landscaping. This application consists of a variation to a previously permitted development for an activity for which a licence under Part IV of the Environmental Protection Agency Act 1992 (as amended by the Protection of the Environment Act, 2003) is required. A Natura Impact Statement (NIS) accompanies this application
Permissiom will consist of the replacement of two existing signs from the Wuxi logo to the MSD logo. Placement and size of new proposed signs are similar (new proposed signs are slightly smaller). On the East Elevation facing the internal IDA roundabout and site entrance, sized approximately 10.5 metres wide and approximately 4 metres high, located at a height of approximately 22.5 metres to the top of the sign. The South Elevation facing the existing main manufacturing facility sized approximately 2.5 metres by 7 metres located at a height of approximately 22.5 metres to the top of the sign. Also, the reskin of existing totem signs, replacement notice board, 2 x MSD Logo at Main and Staff Entrance, diabond sign fitted on each side of pedestrian gate and the addition of an entrance sign to be proposed.
The brief summarizes the pattern across all 1,739 matched decisions within 5 km and includes up to 80 detailed comparables (40 nearest refusals and 40 nearest grants), with extracted reasons, quotes, and available source links. €29 incl. VAT.
Source match
Matched from public planning record 21257The site brief adds up to 80 nearest detailed grants and refusals, extracted source evidence, document links, and a shareable risk summary.
Included in site brief
Included in site brief
Included in site brief
Included in site brief